Page 2 - ESGO - Vulvar cancer - Complete report_fxd2
P. 2

TABLE OF CONTENTS

1 Introduction................................................................................................................................................................ 4
2 Acknowledgements .................................................................................................................................................... 4
3 Method........................................................................................................................................................................ 4

   3.1 Nomination of multidisciplinary international development group ............................................................................ 4
   3.2 Identification of scientific evidence ............................................................................................................................ 5
   3.3 Formulation of guidelines........................................................................................................................................... 5
   3.4 External evaluation of the guidelines - International review....................................................................................... 6
   3.5 Integration of international reviewers comments ........................................................................................................ 6
4 Management of conflicts of interest.......................................................................................................................... 6
5 Summary of guidelines .............................................................................................................................................. 7
   5.1 Diagnosis and referral ................................................................................................................................................. 7
   5.2 Staging system ............................................................................................................................................................ 7
   5.3 Preoperative investigations ......................................................................................................................................... 7
   5.4 Surgical management.................................................................................................................................................. 8
   5.5 Sentinel lymph node procedure................................................................................................................................... 9
   5.6 Radiation therapy........................................................................................................................................................ 9
   5.7 Chemoradiation......................................................................................................................................................... 10
   5.8 Systemic treatment.................................................................................................................................................... 10
   5.9 Treatment of recurrent disease.................................................................................................................................. 10
   5.10 Follow-up ................................................................................................................................................................. 11
6 Diagnosis and referral ............................................................................................................................................. 12
   6.1 Summary of available scientific evidence................................................................................................................. 12
   6.2 Previous initiatives.................................................................................................................................................... 12
   6.3 Development group comments ................................................................................................................................. 12
   6.4 Guidelines................................................................................................................................................................. 12
7 Staging system.......................................................................................................................................................... 13
   7.1 Summary of available scientific evidence................................................................................................................. 13
   7.2 Previous initiatives.................................................................................................................................................... 13
   7.3 Development group comments ................................................................................................................................. 13
   7.4 Guidelines................................................................................................................................................................. 13
8 Preoperative investigations ..................................................................................................................................... 15
   8.1 Summary of available scientific evidence................................................................................................................. 15
   8.2 Previous initiatives.................................................................................................................................................... 16
   8.3 Development group comments ................................................................................................................................. 16
   8.4 Guidelines................................................................................................................................................................. 17
9 Surgical management .............................................................................................................................................. 20
   9.1 Summary of available scientific evidence................................................................................................................. 20
   9.2 Previous initiatives.................................................................................................................................................... 24
   9.3 Development group comments ................................................................................................................................. 24
   9.4 Guidelines................................................................................................................................................................. 25
10 Sentinel lymph node procedure .............................................................................................................................. 26
   10.1 Summary of available scientific evidence................................................................................................................. 26
   10.2 Previous initiatives.................................................................................................................................................... 29

                                                                                          VULVAR CANCER - GUIDELINES 
                                                                                                                 2
   1   2   3   4   5   6   7